Feb 15, 2021
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
Jan 11, 2021
Synlogic Outlines Upcoming Clinical Milestones
Dec 14, 2020
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma
Dec 09, 2020
Synlogic Appoints Michael Heffernan to its Board of Directors
Dec 07, 2020
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering
Nov 05, 2020
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update
Nov 04, 2020
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria
Oct 27, 2020
Synlogic Announces Third Quarter 2020 Conference Call & Webcast
Oct 22, 2020
Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020
Sep 14, 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
Sep 08, 2020
Synlogic to Present at Upcoming Virtual Banking Conferences
Aug 06, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update
Jul 28, 2020
Synlogic Announces Second Quarter 2020 Conference Call & Webcast
Jun 01, 2020
Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors
May 27, 2020
Synlogic Hosts First Virtual R&D Event
May 21, 2020
Synlogic to Host Virtual R&D Event
May 21, 2020
Synlogic Announces Termination of AbbVie Collaboration Agreement
May 08, 2020
Synlogic Reports First Quarter 2020 Financial Results and Provides Business Update
May 04, 2020
Synlogic Announces First Quarter 2020 Conference Call and Webcast
Mar 30, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities